An emerging role for SPAK in NCC, NKCC, and blood pressure regulation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

1. Bartter syndrome: causes, diagnosis, and treatment.International journal of nephrology and renovascular disease · 2018
   Review
2. Ablation of Potassium-Chloride Cotransporter Type 3 (Kcc3) in Mouse Causes Multiple Cardiovascular Defects and Isosmotic Polyuria.PloS one · 2016
   Article
3. Perspective of future drugs targeting sterile 20/SPS1-related proline/alanine-rich kinase for blood pressure control.World journal of cardiology · 2015
   Article
4. Understanding Bartter syndrome and Gitelman syndrome.World journal of pediatrics : WJP · 2012
   Review
5. A SPAK isoform switch modulates renal salt transport and blood pressure.Cell metabolism · 2011
   Article

Corrections and comments

• Comment on
  SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction.2010

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as